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Background: Angiogenesis, the formation of new blood vessels, is essential 
for tumor growth. The inhibition of angiogenesis is therefore emerging as a 
promising therapy for cancer. Two natural products, fumagillin and ovalicin, 
were discovered to be potent inhibitors of angiogenesis due to their inhibition of 
endothelial cell proliferation. An analog of fumagillin, AGM-1470, is currently 
undergoing clinical trials for the treatment of a variety of cancers. The underlying 
molecular mechanism of the inhibition of angiogenesis by these natural drugs 
has remained unknown. 
Results: Both AGM-1470 and ovalicin bind to a common bifunctional protein, 
identified by mass spectrometry as the type 2 methionine aminopeptidase 
(MetAP2). This protein also acts as an inhibitor of eukaryotic initiation factor 2cx 
(elF-2a) phosphorylation. Both drugs potently inhibit the methionine 
aminopeptidase activity of MetAP without affecting its ability to block elF-2a 
phosphorylation. There are two types of methionine aminopeptidase found in 
eukaryotes, but only the type 2 enzyme is inhibited by the drugs. A series of 
analogs of fumagillin and ovalicin were synthesized and their potency for 
inhibition of endothelial cell proliferation and inhibition of methionine 
aminopeptidase activity was determined. A significant correlation was found 
between the two activities. 
Conclusions: The protein MetAP is a common molecular target for both 
AGM-1470 and ovalicin. This finding suggests that MetAP may play a critical 
role in the proliferation of endothelial cells and may serve as a promising target 
for the development of new anti-angiogenic drugs. 
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Introduction 
Angiogenesis, the process of new blood vessel formation, is 
known to play a pivotal role in both physiological states, 
such as wound healing, corpus luteum formation and 
embryonic development, and a variety of pathological 
states, including diabetic retinopathy, arthritis and inflam- 
mation [l-3]. In particular, angiogenesis has been demon- 
strated to be essential for the growth of solid tumors [4,5]. 
Without access to sufficient vasculature, tumor growth is 
restrained as a result of widespread cell death [6-B]. Inhi- 
bition of angiogenesis can therefore be used as an effective 
treatment for cancer. 
Fumagillin (Figure la), a natural product of fungal origin 
[9,10], was discovered to act as a potent inhibitor of angio- 
genesis [ll]. A synthetic analog of fumagillin, O-(chloro- 
acetylcarbamoyl)fumagillol (AGM-1470, also known as 
TNP-470), was found to be less toxic and a 50-fold more 
potent inhibitor of angiogenesis than fumagillin [ll]; this 
compound is currently undergoing clinical trials for a 
variety of cancers. AGM-1470 has been demonstrated 
to cytostatically inhibit capillary endothelial cell growth 
induced by both basic fibroblast growth factor (bFGF) and 
vascular endothelial cell growth factor (VEGF) [12], and 
preferentially inhibit endothelial cell growth in tumor vas- 
culature in VZVO [13]. The molecular mechanism of action 
of ACM-1470 remains unknown, however. 
Ovalicin (Figure la), a sesquiterpene isolated from the 
fungus Pseudorotium ova& [14,15], has been shown to 
exhibit antibiotic, antitumor and immunosuppressive activ- 
ity [16,17]. Little is known about its molecular mechanism 
of action. The structural similarity of fumagillin and ovalicin 
led to the testing of ovalicin for anti-angiogenic activity. 
Ovalicin was found to inhibit angiogenesis with a potency 
that was comparable to that of AGM-1470 [18]. Similarly to 
AGM-1470, ovalicin cytostatically inhibits the proliferation 
of endothelial cells. Whether ovalicin and AGM-1470 share 
the same mechanism of action is not known. 
As both ACM-1470 and ovalicin inhibit the proliferation 
of endothelial cells with high potency, they serve as excel- 
lent probes for elucidating the molecular mechanism of 
regulation of endothelial cell growth. Here, we report that 
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The chemical structures of fumagillin, ovalicin, 
ovalicin photoaffinity label, biotin conjugates 
and synthetic analogs. (a) Fumagillin, 
AGM-1470, and ovalicin. The epoxides at C-3 
of AGM-1470 and ovalicin are highlighted by 
arrows and numbering of the six-membered 
ring system is shown. (b) Ovalicin 
photoaffinity label and its mimic. 
(c) Biotin-fumagillin and biotin-ovalicin 
conjugates. (d) Synthetic analogs of fumagillin 
and ovalicin. 
both AGM-1470 and ovalicin bind covalently to a bifunc- 
tional protein, the type 2 methionine aminopeptidase 
(MetAPZ). The protein is also an inhibitor of eukaryotic 
initiation factor 2a (eIF-2a) phosphorylation. We show 
that both drugs potently inhibit the methionine 
aminopeptidase activity of the protein but neither affects 
its inhibition of eIF-2a phosphorylation. We demonstrate 
that AGM-1470 and ovalicin specifically inhibit type 2 but 
not type 1 methionine aminopeptidase. A significant cor- 
relation between the potency of inhibition-of MetAP 
enzymatic activity and the inhibition of edothelial cell 
proliferation was observed for a number of fumagillin and 
ovalicin analogs. These results suggest that MetAP may 
play an important role in the proliferation of endothelial 
cells and serve as a target for identifying new inhibitors 
of angiogenesis. 
Results 
Detection of a 67 kDa protein that binds to both AGM-1470 
and ovalicin 
The structure/activity relationship of fumagillin, deter- 
mined using a variety of fumagillin analogs [19], suggests 
that the sidechain at the C-6 position can tolerate a 
number of modifications without significant loss of activity 
(Figure la). We therefore attached a radioactive pho- 
toaffinity label to ovalicin at the corresponding position 
(Figure lb). To ensure that this modification does not sig- 
nificantly abrogate the activity of ovalicin, we tested a 
mimic of the photoaffinity label in a bovine aortic endothe- 
lial cell (BAEC) proliferation assay [‘ZO] and found that the 
photoaffinity label mimic retained significant, albeit 
decreased, activity in comparison with ovalicin (data not 
shown). From extracts prepared from BAECs, a number of 
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Figure 2 
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Photoaffinity labeling of BAEC extracts reveals that p67 is a common 
binding protein for both AGM-1470 and ovalicin. Lanes l-3, ovalicin 
photoaffinity labeling of BAEC extracts: 1, no competitor; 2, + 1 pM 
ovalicin; 3, + 1 PM AGM-1470. Lanes 4-6, ovalicin photoaffinity 
labeling of mouse embryo extract: 4, no competitor; 5, + 1 uM ovalicin, 
6, + 1 KM AGM-1470. 
proteins were labeled by the ovalicin photoaffinity probe 
(Figure 2, lane 1). Preincubation of cell extract with excess 
ovalicin led to the disappearance of a single labeled band 
of approximately 67 kDa (p67), suggesting that the label- 
ing of p67 is mediated by the specific binding of ovalicin to 
the protein (Figure 2, lane 2). Significantly, treatment of 
cell extract with AGM-1470 also abrogated p67 labeling, 
suggesting that both AGM-1470 and ovalicin bind 
competitively to the same target protein (Figure 2, lane 3). 
Isolation of p67 from mouse embryo extract 
Having observed p67 as a putative target for both 
AGM-1470 and ovalicin in BAECs, we sought a more easily 
obtainable source of large amounts of proteins for isolation 
of ~67. We examined extracts prepared from mouse 
embryos (14.5 days post conception), reasoning that the 
target of these compounds should be abundant during a 
period of embryogenesis known to involve extensive angio- 
genesis [Zl]. Using the ovalicin photoaffinity probe, an 
increased amount of p67 was indeed detected in mouse 
embryo extracts compared to BAEC extracts (Figure 2, 
lane 4). To facilitate the isolation of ~67, we synthesized 
biotin conjugates of both ovalicin and fumagillin as affinity 
reagents (Figure lc). When tested in the BAEC prolifera- 
tion assay, both the biotin-fumagillin and biotin-ovalicin 
conjugates were found to retain significant activity (data not 
shown). The biotin conjugates were incubated with mouse 
embryonic extract and bound proteins were isolated by the 
addition of immobilized streptavidin. As shown in Figure 3a 
(lanes Z-4) a 67 kDa protein bound by biotin-fumagillin 
was visible upon silver staining of the sodium dodecylsul- 
phate (SDS)-polyacrylamide gel, and its binding was com- 
peted by both AGM-1470 and ovalicin. Similarly, p67 was 
retained by the biotin-ovalicin conjugate bound to immobi- 
lized streptavidin in an AGM-1470- and ovalicin-sensitive 
manner (Figure 3a, lanes 5-7). Thus, the results obtained 
with the biotin conjugates are consistent with the observa- 
tions made with ovalicin photoaffinity labeling, namely that 
p67 binds to both AGM-1470 and ovalicin. 
Identification of p67 as MetAP2/inhibitor of elF-2oc 
phosphorylation 
To obtain a sufficient amount of p67 for identification, 
we scaled up the biotin-fumagillin binding experiment 
and purified -6OOng of p67 from mouse embryo extract. 
We subjected the partially purified p67 to SDS-poly- 
acrylamide gel electrophoresis (PAGE) and excised the 
67 kDa band after silver staining. This sample was sub- 
jected to in-gel digestion with trypsin and the resulting 
tryptic fragments were extracted from the gel [ZZ]. The 
peptide mixture thus obtained was analyzed by matrix- 
assisted laser desorption/ionization-time of flight 
(MALDI-TOF) mass spectrometry. The resulting spec- 
trum exhibited 22 distinct peaks corresponding to 
[M+H]+ ions of peptides (Figure 3b). Those peaks at m/z 
842.52, 882.59 and 1010.37 are common background 
peaks, and m/z 962.43 and 2465.2 represent the internal 
standards (adrenocorticotrophic hormone (ACTH) 4-10 
and 18-39). The remaining 17 m/z values were used to 
search the EMBL protein database and this revealed that 
16 of these values fit those predicted for both the rat and 
human MetAP (Swiss-Prot accession numbers P38062 
and P50579, respectively). The rat and human enzymes 
have also been shown to inhibit the phosphorylation of 
eIF-2a, thus positively regulating protein synthesis 
[23-251. These [M+H]+ ions correspond to 15 different 
tryptic peptides derived from either human or rat 
MetAP2. The peaks at m/z 2136.15 and 2122.11 represent 
the same peptide (452-469) in which the carboxy-termi- 
nal Cys468 has reacted partly with monomeric acry- 
lamide. The only peak unaccounted for, m/x 1228.68, may 
be a contaminant or a peptide from a region that bears a 
post-translational modification. 
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Figure 3 
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Isolation and identification of p67 from mouse 
embryo extracts using biotin-fumagillin and 
biotin-ovalicin conjugates. (a) Detection of 
p67 in mouse embryo extracts (arrow). Mouse 
embryo extracts were incubated with 
competing drugs for 30 min followed by 
incubation with biotin-fumagillin or 
biotin-ovalicin conjugate for 1 h. Immobilized 
streptavidin was added for 1 h. Samples were 
analyzed by SDS-PAGE followed by silver 
staining. Lane 1, immobilized streptavidin 
control; 2, biotin-fumagillin conjugate alone; 
3, biotin-fumagillin conjugate with AGM-1470 
competition; 4, biotin-fumagillin conjugate 
with ovalicin competition; 5, biotin-ovalicin 
conjugate alone; 6, biotin-ovalicin conjugate 
with AGM-1470 competition; 7, biotin-ovalicin 
conjugate with ovalicin competition. 
(b) MALDI-TOF mass spectrum of a tryptic 
digest of ~67. The m/z values are 
monoisotopic. Peaks marked (*) are also 
present in the spectrum from the blank 
experiment. See text for details. 
(c) MetAP is highly conserved among 
eukaryotes. The putative mouse MetAP 
sequence is compared to those of rat, human 
and Saccharomyces cerevisiae. Protein 
sequences were aligned using the program 
MegAlign. The tryptic fragments identified by 
mass spectrometry are overlined. Sequence 
identity is highlighted by shading. 
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Western blot analysis confirms the identity of p67 as MetAP2. 
Samples were prepared as in Figure 3a, transferred to nitrocellulose 
and incubated with rabbit anti-human MetAP polyclonal antibodies 
followed by incubation with anti-rabbit IgG-HRP. Lane 1, 
biotin-fumagillin conjugate alone; 2, biotin-fumagillin conjugate with 
AGM-1470 competition; 3, biotin-fumagillin conjugate with ovalicin 
competition; 4, biotin-ovalicin conjugate alone; 5, biotin-ovalicin 
conjugate with AGM-1470 competition; 6, biotin-ovalicin conjugate 
with ovalicin competition; 7, recombinant MetAP (10 pg). 
The rat MetAP2, a 478 amino acid glycoprotein with a cal- 
culated molecular mass of 53 kDa, has been shown to 
migrate at 67 kDa by SDS-PAGE [23]. No mouse 
homolog of MetAPZ has yet been cloned, but by searching 
the expressed sequence tagged (EST) database, a putative 
open reading frame (ORF) was generated by aligning 
overlapping sequences. Comparison of this putative 
mouse ORF with the known sequences of human, rat, and 
yeast MetAP indicated that this protein is highly con- 
served among eukaryotes (Figure 3~). The three mam- 
malian proteins show >93% sequence identity, and the 
yeast MetAP sequence has >.55% identity with the 
human sequence. All 16 tryptic peptides identified by 
mass spectrometry matched the putative mouse ORF 
exactly. It therefore seemed likely that we had identified 
a mouse homolog of MetAP 
To confirm the identity of the common binding protein for 
both AGM-1470 and ovalicin as MetAP2, we repeated the 
binding assay with both biotin-fumagillin and 
biotin-ovalicin conjugates and analyzed the protein 
retained on streptavidin beads by Western blot with anti- 
human MetAP polyclonal antibodies. We found that the 
mouse p67 which was bound by both biotin-fumagillin and 
biotin-ovalicin conjugates reacted with the anti-human 
MetAPZ antibodies (Figure 4, lanes 1,4). Competition with 
AGM-1470 and ovalicin led to the elimination of the cross- 
reacting band (Figure 4, lanes 2,3,5,6). The mouse p67 was 
also shown to migrate on SDS-PAGE at the same position 
as authentic human recombinant MetAP These experi- 
ments established that the common 67kDa binding 
protein of both fumagillin and ovalicin is identical to 
MetAPZ/inhibitor of eIF-2a phosphorylation. 
AGM-1470 and ovalicin bind covalently to MetAP 
As both AGM-1470 and ovalicin possess potentially reactive 
epoxide groups (Figure la, arrows) that are capable of cova- 
lently modifying amino acid sidechains, we decided to 
112345676 
The biotin conjugates of fumagillin and ovalicin form stable adducts 
with MetAP2. Recombinant human MetAP was incubated with the 
biotin conjugates in the presence or absence of competitors. Samples 
were denatured, boiled in a buffer containing SDS and 
5-mercaptoethanol, and transferred to nitrocellulose. (a) The biotin 
conjugates bound to the protein were detected using 
streptavidin-HRP and (b) MetAP was detected using anti-human 
MetAP followed by anti-rabbit IgG-HRP. B-F, biotin-fumagillin; 
B-O, biotin-ovalicin; AGM, AGM-1470; oval, ovalicin. 
determine whether these drugs indeed bind to MetAP 
covalently. Thus, the biotin conjugates were incubated 
with recombinant human MetAP alone, or in the presence 
of either AGM-1470 or ovalicin. The protein samples were 
boiled in a sample buffer containing SDS and P-mercap- 
toethanol, subjected to SDS-PAGE, and transferred to 
nitrocellulose. Probing directly with streptavidin-horserad- 
ish peroxidase (HRP) allowed the visualization of the 
protein samples that had been incubated with the 
biotin-fumagillin or biotin-ovalicin conjugates, but not 
those that had been incubated with free biotin or in the 
presence of competitors (Figure 5a). As a control, the pres- 
ence of MetAP in each sample was confirmed using anti- 
MetAP antibodies (Figure Sb). As the drug-protein 
complex is maintained under denaturing conditions, these 
results strongly suggest that AGM-1470 and ovalicin bind to 
MetAP covalently. 
Assessment of the effect of AGM-1470 and ovalicin on the 
two activities of MetAP 
As MetAP is a bifunctional protein, we wanted to assess 
the effect of AGM-1470 and ovalicin on its two activities. 
We first tested the effect of AGM-1470 and ovalicin on 
the methionine aminopeptidase activity of recombinant 
human MetAP Using a tetrapeptide substrate [26], we 
found that both drugs potently inhibit the methionine 
aminopeptidase activity of MetAPZ. The IC,, values were 
estimated at 1 nM for AGM-1470 and 0.4 nM for ovalicin 
when 1 nM recombinant human MetAP was used in the 
assay (Table 1). 
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Table 1 
Inhibition of BAEC proliferation and MetAP enzymatic activity 
by fumagillin and ovalicin analogs. 
Compound Proliferation IC,, (nM) MetAP IC,, (nM) 
AGM-1470 0.037 i10.0024 i.Of0.3 
Ovalicin 0.018 f 0.0059 0.4 k 0.2 
FOS-72 0.013+0015 6+2 
FOS-68 0.46kO.26 2.OkO.8 
FOS-69 0.31 kO.066 0.10f0.03 
FOS-70 0.12io.01 3.5k1.8 
FOS-37 9.5rt4.6 8+2 
FOS-34 2.2k1.4 4+1 
FOS-64 1 lOrt18 3,000+ 1,000 
FOS-67 40+4 400f200 
FOS-201 56+34 45f12 
FOS-202 2,800 rt 2,300 5,000+2,000 
IC,, values were calculated as the average of at least three 
experiments fit using Deltagraph Pro 3.5 software. 
In addition to its methionine aminopeptidase activity, 
MetAP has been shown to inhibit the phosphorylation of 
eIF-Za by heme-regulated inhibitor kinase (HRI) z?z vitro 
[27,28]. Initial attempts to determine the effect of 
AGM-1470 and ovalicin on this activity of MetAP gave 
ambiguous results as these drugs appeared to stimulate 
both the autophosphorylation of HRI and its phosphoryla- 
tion of eIF-2a. This result was probably due to the nonspe- 
cific modification of cysteine sidechains by both drugs 
because a number of thiol-modifying reagents, including 
N-ethylmaleimide, have been shown to stimulate the 
kinase activity of HRI [29]. To circumvent this problem, 
Figure 6 
we took advantage of the irreversible nature of MetAP 
modification by AGM-1470 and ovalicin. We incubated 
recombinant human MetAP with AGM-1470 and dialyzed 
the modified protein extensively to remove residual free 
AGM-1470. When the drug-treated MetAP was assayed 
for MetAP activity, it was completely inactive, whereas a 
control treated with the carrier solvent (ethanol) retained 
full activity (data not shown). The dialyzed MetAP 
samples, either unmodified or modified with AGM-1470, 
were subsequently examined for their ability to inhibit 
eIF-2a phosphorylation by HRI. As shown in Figure 6, 
MetAP bound by AGM-1470 is as effective as unbound 
MetAP in inhibiting phosphorylation of eIF-Zcx by HRI, 
without affecting HRI autophosphorylation. This experi- 
ment ruled out the possibility that modulation of eIF-‘2a 
phosphorylation by MetAPZ is directly responsible for the 
inhibition of endothelial cell proliferation by AGM-1470. 
Determination of the specificity of AGM-1470 and ovalicin 
for MetAP 
Two types of MetAPs have been found in eukaryotes, 
including the yeast SacclZaromyces cereuisiae [24,2.5,30-321. 
The fact that we detected binding of MetAP2, but not 
the type 1 enzyme MetAPl, to AGM-1470 and ovalicin 
using photoaffinity labeling and affinity purification sug- 
gests that these drugs are specific for MetAP2. To further 
test the specificity of these drugs, we plated both wild- 
type and mutant yeast strains lacking either MetAPl 
(mapl) or MetAP (ma&?) onto media containing the two 
drugs. Although wild-type and map2 mutant yeast are 
resistant to either 50 nM AGM-1470 or 50nM ovalicin, 
the growth of the map1 mutant is completely inhibited by 
these drugs (Figure 7). These results indicate that yeast 
MetAPZ, but not MetAPl, is a target for both ACM-1470 
and ovalicin in viva. 
(a) 1 2 3 6) 
120 
100 
Drug binding does not alter the protective effect of MetAP on elF-Pa phosphorylation. (a) Autoradiogram of elF-2a phosphorylation by HRI. Lane 
1, elF-2a + HRI; 2, elF-2a + MetAP + HRI; 3, elF-2cx + MetAP2-AGM-1470 + HRI. (b) Quantification of HRI autophosphorylation. 
(c) Quantification of elF-2a phosphorylation. Numbering for (b) and (c) is as for (a). 
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Figure 7 
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Specificity of AGM-1470 and ovalicin for MetAP in yeast. Wild-type 
(WT), mapl, and map2 yeast strains were plated on the yeast growth 
medium YEPD, or YEPD containing either 50 nM AGM-1470 or 50nM 
ovalicin. The plates were incubated at 30°C for four days before being 
photographed. 
In addition to the yeast growth experiments in viva, we 
also tested AGM-1470 and ovalicin with recombinant 
yeast MetAPl and MetAPZ in vitro. We observed no inhi- 
bition of MetAPl activity using up to 10 PM AGM-1470 
and ovalicin. In comparison, the yeast MetAP enzyme 
was completely inhibited at concentrations as low as 5 nM, 
consistent with the in viva results indicating that the drugs 
are specific for MetAPZ. 
Relationship between the inhibition of MetAP activity and 
the inhibition of endothelial cell proliferation by fumagillin 
and ovalicin analogs 
Given that both ACM-1470 and ovalicin specifically 
inhibited the enzymatic activity of MetAP without 
affecting its protective effect on eIF-2a phosphorylation, 
we suspected that this effect mediated the anti-angiogenic 
activities of these drugs. As a first step to test this hypo- 
thesis, we synthesized a series of analogs of both fumag- 
illin and ovalicin, including those substituted at the C-6 
position and those in which the terminal epoxide has been 
opened (Figure Id). These analogs were tested for the 
inhibition of MetAPZ activity in vitro and inhibition of 
BAEC proliferation in cell culture (Table 1). A significant 
correlation (Student’s t test P >O.OOl) was found between 
the potency of the inhibition of BAEC proliferation and 
the potency of the inhibition of methionine aminopepti- 
dase activity (Figure 8). Importantly, no derivative was 
Figure 8 
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Pharmacological correlation between the inhibition of the methionine 
aminopeptidase activity of MetAP and the inhibition of BAEC 
proliferation by fumagillin and ovalicin analogs. Values from Table 1 
were plotted using Cricket Graph software. 
found which showed high potency in one assay but no 
activity in the other. This correlation provides further 
support to the hypothesis that the inhibition of MetAP 
enzymatic activity mediates the anti-angiogenic activity of 
AGM-1470 and ovalicin. 
Discussion 
We have detected a 67 kDa protein, ~67, from BAECs and 
mouse embryonic extracts using a photoaffinity probe 
derived from ovalicin. The labeling of p67 by the ovalicin 
photoaffinity probe was sensitive to competition by both 
ovalicin and AGM-1470. Using biotin conjugates derived 
from the two inhibitors, we isolated p67 from mouse 
embryonic extracts and identified it as MetAPZ using 
MALDI-TOF mass spectrometry and a database search. 
The identity of p67 was confirmed using an anti-MetAP 
polyclonal antibody. MetAP is thus a common target for 
AGM-1470 and ovalicin. 
MetAP is a bifunctional protein. In addition to its 
methionine aminopeptidase activity, MetAP has been 
shown to regulate protein synthesis by affecting the phos- 
phorylation state of eIF-2a. We showed that the binding 
of AGM-1470 does not affect this regulatory activity of 
MetAP2. This result is in agreement with earlier studies 
demonstrating that AGM-1470 did not block proliferation 
by affecting gross protein synthesis [33]. Thus, the anti- 
angiogenic activity of AGM-1470, and probably that of 
ovalicin, are not directly mediated by inhibition of 
general protein synthesis. 
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Both AGM-1470 and ovalicin were shown to potently 
inhibit the methionine aminopeptidase activity of MetAP 
using a peptide substrate. A series of analogs were synthe- 
sized from fumagillin and ovalicin with different potencies 
for the inhibition of endothelial cell proliferation. When 
these analogs were tested for the inhibition of MetAPZ 
aminopeptidase activity in vitro, a strong correlation was 
observed between these two activities. We note that the 
IC,, values for MetAP inhibition in vitro are an order of 
magnitude higher than the corresponding IC,, values for 
inhibition of endothelial cell proliferation. This discrep- 
ancy is due in large part to the higher concentrations of 
protein required for the enzymatic assay in vitro. The small 
deviation of some compounds from this correlation may be 
attributable to differences in cell permeability and metabo- 
lism within the cell. Although the small number of analogs 
tested precludes the establishment of an absolute correla- 
tion, no compound that is active in one assay and not in the 
other has yet been found, supporting the notion that inhi- 
bition of MetAP enzymatic activity is responsible for the 
anti-proliferative effects of AGM-1470 and ovalicin. 
Earlier work has focused on the clarification of the anti- 
proliferative effects of AGM-1470 at the cellular level. 
AGM-1470 has been demonstrated to potently inhibit 
endothelial cell proliferation induced by both bFGF and 
VEGF [12]. The inhibition of endothelial cell proliferation 
by these inhibitors exhibits a biphasic character. The inhi- 
bition was cytostatic in the first phase with an IC,, of 
45pM. At concentrations above 90 PM, AGM-1470 
became cytotoxic [33]. The cytostatic inhibition has been 
shown to block the entry of cells into the Gl phase of the 
cell cycle [ZO]. At the molecular level, it has been demon- 
strated that the treatment of vascular endothelial cells with 
AGM-1470 inhibits the activation of the cyclin-dependent 
kinases cdc2 and cdk2 and the phosphorylation of the 
retinoblastoma gene product [34]. Early Gl events such as 
protein tyrosyl phosphorylation and the expression of 
immediate early genes such as c-fos and c-myc were unaf- 
fected, however. AGM-1470 does not affect cdk activity in 
vitro, arguing that AGM-1470 exerts its effects prior to cdk 
activation. Inhibition of MetAP may therefore lead to the 
disfunction of key molecules involved in the cell cycle pro- 
gression of endothelial cells and other sensitive cell types 
prior to cdk activation, leading to cell cycle arrest. 
Methionine aminopeptidase is an essential enzyme in 
both prokaryotes and eukaryotes. A single gene for MetAP 
is known in Eschediu coli and its knockout leads to invia- 
bility [35]. The removal of the amino-terminal methionine 
is known to be important for post-translational’modifica- 
tion of many proteins in eukaryotes. Amino-terminal 
myristoylation requires the processing of the amino-termi- 
nal methionine and has been shown to affect the function 
of many proteins, including protein kinases such as Src 
[36], protein phosphatases such as calcineurin B [37], and 
proteins involved in the regulation of protein secretion 
such as ADP-ribosylation factors [38]. Another important 
function of processing of the amino-terminal methionine 
is the regulation of protein stability and turnover accord- 
ing to the N-end rule [39]. Inhibition of methionine 
aminopeptidase activity by these drugs therefore may 
disrupt endothelial cell cycle progression due to the dis- 
regulation of post-translational processes required for the 
function of MetAPZ substrates. It remains to be estab- 
lished whether the inhibition of endothelial cell prolifera- 
tion is mediated through the inhibition of either 
post-translational modification, disregulation of protein 
stability, or both. 
We have shown that AGM-1470 and ovalicin specifically 
target MetAP but do not affect MetAPl in vitro and in 
viva in yeast. Although the two MetAPs from yeast show 
limited substrate specificity in vitro [32], specificity may 
exist in viva as a result of their different subcellular localiza- 
tion. Both MetAPl and MetAP possess domains at their 
amino termini that are thought to be involved in mediating 
protein-protein interactions. MetAPl possesses two zinc 
finger motifs at the amino terminus which have been 
shown to be required for full function in viva [40], whereas 
MetAP amino-terminal sequences contain polylysine 
blocks and an aspartic acid block that are also present in 
human eIF-2P and the yeast protein Sui 3 [23]. These 
residues may mediate the specific association of MetAP 
with the eIF-2 complex or other cellular proteins. In yeast, 
the knockout of MetAPl or MetAP leads to a slow growth 
phenotype, and disruption of both MetAPs is lethal [32]. 
Although MetAPl can substitute for MetAP in yeast, the 
situation is likely to be different in drug-sensitive mam- 
malian cell types. There could be MetAPZ-specific sub- 
strates that have a unique role in drug-sensitive cells, It is 
also possible that the compounds are metabolized differ- 
ently in different cell types; the metabolism of these com- 
pounds could be affected by several factors including the 
expression level of epoxide hydrolases that may serve to 
inactivate these epoxide-containing drugs [41]. 
The effects of AGM-1470 and ovalicin are not entirely con- 
fined to endothelial cells. AGM-1470 has been shown, for 
example, to inhibit the proliferation of human embryonic 
fibroblasts [ll]. Both AGM-1470 and ovalicin have also 
been shown to modulate the immune response. Ovalicin 
was initially shown to be active in several assays for 
immunosuppression. It reduces the number of antibody- 
producing cells in the spleens of mice, it is active in experi- 
mental encephalomyelitis in rats, and it prolongs the 
survival of skin allografts [42-44]. At the cellular level, it 
was shown to inhibit the mixed lymphocyte reaction 
(MLR) at concentrations as low as 3.0 pM [45]. Fumagillol 
(FOS-37; Figure Id), the alkaline hydrolysis product of 
fumagillin, has also been shown to suppress a mouse MLR 
with an IC,, of 250 nM [46]. Inversion of the stereo-center 
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at C-6 and demethylation at C-5 greatly increase this 
effect, giving an IC,, of 34 nM for the corresponding 
natural product FR65814 [46]. On the other hand, 
AGM-1470 has been shown to stimulate B-cell prolifera- 
tion upon stimulation with phytohemagglutinin (PHA) in 
the presence of T-cells [47,48]. It remains to be estab- 
lished whether ovalicin also stimulates B-cell proliferation 
and whether AGM-1470 inhibits MLR. Whether inhibition 
of MetAP activity by these compounds underlies their 
immunomodulatory effect also awaits further investigation. 
We have shown that both AGM-1470 and ovalicin form 
covalent complexes with MetAP2. The two biotin conju- 
gates were shown to remain associated with the protein 
under denaturing conditions. In addition, incubation of 
MetAP with AGM-1470 rendered the protein enzymati- 
tally inactive even after extensive dialysis. This covalent 
interaction is likely to be mediated by the reactive epox- 
ides present in these compounds [49]. Indeed, opening of 
the terminal epoxide reduces the anti-angiogenic activity 
and the inhibition of methionine aminopeptidase activity 
of the compounds by several orders of magnitude 
(Figure Id; Table l), suggesting that the terminal 
epoxide may be involved in the covalent modification of 
MetAP2. This terminal epoxide may react with a cysteine 
residue present in or near the active site of MetAP2. 
Interestingly, the recombinant human MetAP has been 
shown to be sensitive to sulfhydryl-modifying reagents 
such as HgCl, and p-hydroxymercuribenzoic acid 
(Y.-H.C., unpublished observations). One major differ- 
ence between the two types of eukaryotic MetAPs is an 
insertion of 64 amino acid residues towards the carboxyl 
terminus of the catalytic domain of the type 1 enzyme. It 
is possible that this insertion is responsible for the selec- 
tivity of AGM-1470 and ovalicin for the type 2 enzyme. 
Interestingly, there is a cysteine within this insertion, 
conserved between yeast, rat, human and the putative 
mouse MetAP2, that may be a candidate for covalent 
modification by these inhibitors [24&S]. The exact nature 
of the interaction between AGM-1470 or ovalicin and 
MetAP awaits further characterization. 
Two types of MetAPs are presently known in eukaryotes. 
A database search of the entire genome of yeast S. cere- 
uisiae did not reveal any new members of this family, indi- 
cating that yeast possesses only two types of MetAPs. In 
higher eukaryotes, however, the MetAP family is likely to 
be larger. In fact, a mouse proliferation-associated protein 
was recently cloned and found to have significant homol- 
ogy to human MetAP [SO]. It is not known whether the 
proliferation-associated protein possesses MetAP activity 
and whether it is required for cell cycle progression. 
Although we did not observe binding of a 38kDa protein 
to either the photoaffinity probe of ovalicin or the biotin 
conjugates of both AMG-1470 and ovalicin, it remains 
to be verified whether this MetAPZ homolog binds to 
AGM-1470 and ovalicin, and if it does, whether the 
binding mediates the inhibition of endothelial cell prolif- 
eration and immunomodulation by these drugs. Once 
MetAP or its homolog is proven to be the physiological 
target for AGM-1470 and ovalicin, elucidation of the phys- 
iological function of the target protein in cell cycle pro- 
gression, including its relevant substrates in endothelial 
cells, will offer insight into the regulation of endothelial 
cell proliferation and facilitate the identification of new 
anti-angiogenic agents for the treatment of cancer. 
Significance 
Angiogenesis plays a pivotal role in tumor growth and 
metastases. The inhibition of angiogenesis is emerging 
as a promising new strategy for the treatment of cancer. 
Because endothelial cell proliferation is necessary for 
angiogenesis, an understanding of the molecular mecha- 
nism of regulation of endothelial cell proliferation will 
offer new targets for inhibiting angiogenesis. Two struc- 
turally related inhibitors, AGM-1470 and ovalicin, 
potently inhibit endothelial cell proliferation, thus 
serving as useful molecular probes for elucidating the 
mechanism of endothelial cell proliferation. We found 
that both AGM-1470 and ovalicin bind to a common 
protein target, the type 2 methionine aminopeptidase 
(MetAP2), which also possesses a second function, 
inhibition of eukaryotic initiation factor 2a (eIF-2a) 
phosphorylation. Both drugs were found to bind cova- 
lently to MetAP and inhibit its methionine aminopepti- 
dase activity without affecting its inhibition of eIF-2a 
phosphorylation. The type 1 enzyme, MetAPl, was not 
inhibited by the drugs, suggesting that the interaction 
between the drugs and MetAP is highly specific. These 
results revealed that MetAP may play an important 
role in endothelial cell proliferation and it may serve as 
a target for identifying novel inhibitors of angiogenesis 
for the development of anticancer drugs. 
Materials and methods 
Synthesis of fumagillin and ovalicin analogs 
All analogs of fumagillin, including AGM-1470, were synthesized 
according to literature procedures [19]. All analogs of ovalicin and the 
biotin-fumagillin and biotin-ovalicin conjugates were synthesized using 
modified procedures. All compounds were characterized by ‘H nuclear 
magnetic resonance (NMR), IR and mass spectrometry. The photoaffin- 
ity label of ovalicin was synthesized from its corresponding free amine 
by analogy to previous reports [51]. The details of the synthesis and 
characterization of the analogs will be reported elsewhere. 
Photoaffinity labeling 
Cell or tissue extract (10 1.11; 10 mg/ml of total protein concentration) 
was added to 5 ul labeling buffer (20 mM TrisHCI, pH 7.5, 100 mM 
NaCI), 5 1-11 5 x cold competitor drug or carrier control (1% EtOH in 
labeling buffer), and 5 1.11 ovalicin photolabel (0.2 pCi/~l in 20% 
MeOHlddHzO; 201 OCilmmol) in the absence of direct light. Reaction 
mixtures were incubated on ice in the dark for 1 h and then irradiated at 
254 nm (0.2J/cm2). Reactions were quenched by adding 1.5 ~1 p-mer- 
captoethanol followed by 7.5 ul 5 x SDS sample buffer and heated in a 
boiling water bath for 3 min. Samples were analyzed by 10% 
SDS-PAGE, followed by autoradiography. 
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BAEC proliferation assay 
BAECs were detached from tissue culture flasks by trypsin and plated 
into 96 well plates at a density of 2000 cells per well. After the cells 
adhered to the plate, compounds dissolved in ethanol (final concentra- 
tion of 0.5%) were added to the cultures. Three days later, 25 ~1 of 
2.5 mglml (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
(MTT) solution was added to the cultures. After an additional 4 h incuba- 
tion, 100 ~1 of 10% SDS/O.01 N HCI solution was added to the culture. 
The absorbance at 600 nm was determined 12 h later using a Titertek 
Multiscan Plus plate reader. 
Affinity binding assay 
Mouse embryo extracts were prepared from 14.5 days post concep- 
tion. mouse embryos. Embryos were dissected and dounce homoge- 
nized (30 strokes) in 4 ml/g lysis buffer (20 mM Tris.HCI, pH 7.1, 
100 mM KCI, 0.2% Triton X-l 00, 2 @g/ml leupeptin, 2 pg/ml aprotinin, 
2 pglml soybean trypsin inhibitor). Lysates were centrifuged at 
10,000 x g for 20 min. The resulting supernatant was centrifuged at 
50,000 x g for 30 min. The supernatant was either used immediately or 
frozen at -80°C for storage. An aliquot of extract (200 ~1) was incu- 
bated for 30 min with 50 PM competitor or ethanol control at 4°C. Fol- 
lowing competition, the extract was incubated with the conjugate 
ligands (0.2-l FM final concentration) for 1 h at 4°C. Immobilized 
streptavidin (40 ~1; 1 :l in lysis buffer) was added and the mixture was 
incubated at 4°C for 1 h. The beads were pelleted at 10,000 rpm in a 
microcentrifuge for 5 min and washed twice with 600 ~1 lysis buffer for 
5 min. 40 ~1 of 1 x SDS sample buffer was added and the samples 
were boiled for 10 min. 25 ,uI of the mixture was loaded on a 12% 
SDS-PAGE gel and silver stained. 
Identification of p67 by mass spectrometry 
The affinity binding experiment was scaled up by using 3 ml of mouse 
embryo extract (16 mg/ml) and increasing the amount of biotin-fumag- 
illin, immobilized streptavidin and other reagents and solutions propor- 
tionally. The partially purified p67 was released from immobilized 
streptavidin by boiling in sample buffer for 10 min before loading onto a 
10% SDS-polyacrylamide gel. After electrophoresis, the gel was silver 
stained to visualize ~67. The 67 kDa band was excised, reduced and 
alkylated with iodoacetamide, followed by digestion with trypsin and 
extraction as previously described [52]. 
The extract of the tryptic peptide mixture was dried in a Speedvac and 
the residue was dissolved in 3.5 ~1 of 7% aqueous formic acid. About 
0.5 ~1 of this solution and 0.5 ~1 of the standard (ACTH 4-l 0 and 
18-39, 50-l 00 fmol each) were placed onto a thin film of a-cyano-4- 
hydroxycinnamic acid deposited on the sample plate of a PerSeptive 
Biosystems Voyager-Elite MALDI-TOF mass spectrometer and evapo- 
rated to dryness. Figure 3b represents the spectrum obtained by sum- 
mation of 256 N, laser pulses. The instrument was operated in the 
reflectron mode with delayed extraction [53]. Under these conditions, 
the resolution is >4000, sufficient to resolve the isotopic multiplets 
with the mass accuracy being over 50 ppm. 
The human MetAP sequence (Swiss-Prot accession number P50579) 
was used to search the EST database. A total of 13 overlapping mouse 
clones were found (Accession numbers: AA1 75951, AA1 72540, 
AA023796, AA1 85067, AA1 75099, AA1 38570, L26708, AA204267, 
AA1 75131, AA21 2018, AA242695, AA408613 and D21545). They 
were assembled into single cDNA encoding the full length MetAPP. 
Western immunoblotting 
Recombinant human MetAP was expressed and purified as previously 
reported [26]. Samples were transferred to nitrocellulose at 50V for 1 h 
at 4°C. The nitrocellulose was treated overnight with blocking solution 
(5% BSA, 2% nonfat milk, 0.02% NaN, in PBS). The membrane was 
incubated with rabbit anti-human MetAP polyclonal antibodies (1:500) 
for 1 h at room temperature, followed by incubation with sheep anti- 
rabbit IgG-HRP. MetAP was visualized with the chemilluminescent 
ECL kit (Amersham) as described in the manufacturer’s instructions. 
Detection of biotin-fumagillin and biotin-ovalicin covalent/y 
associated with MetAP 
Recombinant human MetAP (100 ng) was incubated in 40 ~1 binding 
buffer (20 mM TrisHCI, pH 7.1, 100 mM KCI, 0.2% Triton X-l 00) in 
the presence or absence of competitors for 1 h followed by incubation 
with the biotin conjugates (1 PM) at 4°C for 2 h. An aliquot of 2 x SDS 
sample buffer (40 ~1) was added, and the samples were boiled for 
10 min. Following SDS-PAGE, the samples were transferred to nitro- 
cellulose at 50V for 1 h at 4°C and blocked overnight in blocking solu- 
tion (5% BSA, 2% nonfat milk, 0.02% NaN, in PBS). The membrane 
was incubated with rabbit anti-human MetAP antibodies (1:500) for 
1 h at room temperature, followed by incubation with sheep anti-rabbit 
IgG-HRP or incubated with streptavidin-HRP (1:lOOO) for 1 h and 
visualized with the chemilluminescent ECL kit (Amersham), according 
to the manufacturer’s instructions. 
MetAP enzymatic assay 
Recombinant human MetAP was expressed and purified from insect 
cells as previously described [26]. To determine the effect of ovalicin 
and AGM-1470 as well as their derivatives on MetAP activity, various 
amounts of these inhibitors was added to buffer H (10 mM Hepes, 
pH 7.35, 100 mM KCI, 10% glycerol, and 0.1 M Co2+) containing 
1 nM of purified human MetAPP, and incubated at 37°C for 30 min. To 
start the enzymatic reaction, Met-Gly-Met-Met was added to a con- 
centration of 1 mM to the reaction mixture. Released methionine was 
quantified at different time points (0, 2, 3 and 5 min) using the method 
of Zuo et a/. [401. 
Phosphorylation assay for elF-2a 
Recombinant human MetAP was incubated with AGM-1470 or 
ethanol carrier alone and dialyzed into 20 mM TrisHCI, pH 7.8, 
100 mM KCI. Modified or control MetAP (0.6 pg) was incubated 
with purified elF-2 (0.3 pg) in 20 mM TrisHCI, pH 7.8, 40 mM KCI, 
and 2 mM MgAc, on ice for 1 h. Recombinant HRI (0.25 ng) and 
[Y-~*P]ATP were then added to a final total volume of 20 ~1 and the 
reaction mixture was further incubated at 37°C for 10 min. The 
labeled elF-2a was analyzed by 10% SDS-PAGE followed by 
autoradiography. The phosphorylated bands were quantified by NIH 
Image 1.60 software. 
Effect of AGM-1470 and ovalicin on yeast growth 
The wild-type [YPH500 (MATa ura3-52 1~~2-801 ade2-101 trpl -A63 
his3-A200 leu2-Al), the map7 null [XLPlOl (mapl:: HIS3)], and the 
map2 null [XLPPOl (map2::URA3)] yeast cells were grown in YEPD at 
30°C to A,,, of 1, and plated out on a YEPD plate, and YEPD plates 
containing 50 nM ovalicin or AGM-1470. The plates were incubated at 
30°C for four days. 
Note added in proof 
A paper reporting the identification of MetAP as the binding protein 
for fumagillin has appeared (Sin N., et al, & Crews, CM. (1997). The 
anti-angiogenic agent fumagillin covalently binds and inhibits the 
methionine aminopeptidase, MetAPP. Proc. /Vaf/ Acad. Sci USA 94, 
6099-6103). We thank Craig Crews for communicating information to 
us prior to publication. 
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